Glaukos Corporation Share Price & Technical Analysis
GKOS · $120.2 (-13.52%)
Healthcare / Medical Devices
$120.2
-13.52%
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aq…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-16% return in May, 16% avg return in past 3 year May month.
11% return in 2026, 47% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 4% | 1% | -9% | 32% | -16% | – | – | – | – | – | – | – | 11% |
| 25 | 4% | -22% | -18% | -4% | 12% | 10% | -16% | 14% | -14% | 6% | 21% | 7% | -1% |
| 24 | 13% | -1% | 6% | 1% | 17% | 5% | -1% | 21% | -4% | 2% | 8% | 7% | 74% |
| 23 | 11% | -4% | 6% | -5% | 20% | 25% | 9% | -2% | 0% | -9% | -6% | 24% | 69% |
| 22 | 18% | 4% | 5% | -18% | -14% | 10% | 19% | -9% | 10% | 4% | -18% | -7% | 4% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Weak
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$7.89B
P/E ratio
—
52W high
$148.1
52W low
$73.16
Volume
26,98,483
Beta
0.95
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Glaukos Corporation share price today?
- Glaukos Corporation (GKOS) last traded around $120.2 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does GKOS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for GKOS. Download the app for real-time alerts.
- How can I analyze Glaukos Corporation stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.